A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system is worn on the body for approximately three days at a time and allows ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes ...

The producer of the Omnipod Insulin Management System ... in the sector at large, including Insulet. Beta is also innovating in the space, by providing pumps which use adaptive and closed-loop ...

On Thursday, Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02. The automated insulin delivery ...

However, adjusted for these distributor distortions, US Omnipod ... Big picture: Insulet remains locked in a race with Medtronic and especially Tandem with its new Mobi insulin pump, to capture ...

And given we are the only insulin pump in the diabetes space ... constant currency revenue growth for Insulet. The revenue growth was comprised of U.S. Omnipod growth of 21% and International ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps. The company produces and sells Omnipod, an automated insulin ...

Insulet's Omnipod 5 device is the first ... beating analysts' estimates of $582.8 million. Sales of Omnipod insulin pumps came in at $585.7 million for the fourth quarter, compared with analysts ...